Technical Analysis
Earnings-Per-Share and Revenue Growth Between 2025 & 2028
Health
Insiders
Action
Targets in 2028
- Price for Morningstar
MORN has fallen just below my "crash" simple moving average zone (green lines). The "major crash" zone (gray lines) extends down between $136 - $119 and there is a high possibility the price may dip that low in the near-term (especially to close the last price gap since the pandemic at $115). Long-term, given the potential earnings and revenue growth, it looks undervalued at its current price.
Earnings-Per-Share and Revenue Growth Between 2025 & 2028
- Projected Earnings-Per-Share Growth: +60.1% (from $9.43 in 2025 to $15.13 in 2028)
- Projected Revenue Growth: +29.1% (from $2.4 billion in 2025 to $3.1 billion in 2028)
Health
- Debt-to-Equity: 0.7x (good)
- Altman's Z-Score/Bankruptcy Risk: 4.8 (excellent / low risk)
- Quick Ratio/Ability to pay current bills: 1 (okay, ideally between 1.5 and 3)
Insiders
- Major selling (**warning**) and no buying
Action
- Due to the good growth potential of
MORN and the technical analysis position, I am personal creating a starter position at $154.15. I am not positive the price will stay in the "crash" zone, though. If it does fall into the "major crash" area and close the $115 gap, a heavier position will be opened at that level.
Targets in 2028
- $175.00 (+13.5%)
- $197.00 (+27.8%)
Trade active
Target #1 reached resulting in a +13.5% gain.Trade closed: target reached
Closed out of entire position at $185.50 for a final +17.1% gain. Hoping for a better entry if this crashes near $115. If not, all good. If you enjoy this idea, please follow for more: tradingview.com/u/WorthlessViews/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
If you enjoy this idea, please follow for more: tradingview.com/u/WorthlessViews/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
